Leading International Medical Cannabis Business

Expressions of Interest By:


Project Indica

Hilco are pleased to offer for sale the business and assets of a leading international medical cannabis group providing clinical care and pharmacy dispensing in the UK and Australia, along with own leading product brand.

The Opportunity

  • Operating in one of Europe’s fastest growing industries and forming part of a multi-million global marketplace
  • A vertically integrated scalable business facilitating patient access to medical cannabis in the UK and Australia
  • The Group has three main business units spanning product supply, clinical care and pharmacy dispensing
  • Established market presence with proven track record and opportunities to expand into other markets

The Business

  • Founded in 2019 as a pioneer within the newly created UK medical cannabis market following its legalisation in November 2018, the business has established itself as one of the largest operators in the UK
  • Trading across a number of wholly owned subsidiary companies the group operates a direct to consumer business model for the supply, prescription and pharmacy dispensing of medical cannabis products
  • Income generated from three main streams comprising product sales, clinics and online pharmacy dispensing
  • Recent entrant into the Australian market with clinics and wholesale revenues
  • Experienced management team and established workforce
  • Significant brand equity established over the Company’s trading period
  • Current run rate of c.£10m per annum
  • Revenues for Y/E 30th September 2023 c.£8.2m and c.£7.7m for Y/E 2022

Group Assets

The Group’s assets include:

The Subsidiary Operating Companies – The group comprises a number of wholly owned subsidiary operating companies, which include the product brand range, clinical care and pharmacy dispensary businesses.

Intellectual Property Assets – The established brand name and trademarks, copyright in the website content and domain names; and existing policies and protocols produced in relation to compliance and governance as a regulated business. In addition, the Company has developed a custom built in-house pharmacy tech platform and a training programme for Doctors.

The Licences – The company holds all the required regulatory licences and permits for business operations within the relevant subsidiary companies.

Goodwill – The goodwill established since the formation of the business.

Sale Process and Further Information

On receipt of a signed non-disclosure agreement (NDA), access will be provided to a virtual data room housing additional information. To access the NDA, please click the link, sign and return via email to ahart@hilcoglobal.eu and apercival@hilcoglobal.eu

Key Terms & Conditions

By offering the bidder acknowledges that Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets. Such sale will be without any warranties, expressed or implied. The information provided has not been verified by Hilco and bidders are deemed to have carried out their own due diligence. Hilco’s full Terms and Conditions apply.


Anthony Hart MRICS

Associate Director

London Office

+44 (0) 7513 822654


Roland Cramp MRICS

Managing Director

London Office

+44 (0) 7710 152668